Skip to main content

Publications

Publications

    Tetrodotoxin-Sensitive Neuronal-Type Na+ Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. Munger MA, Olğar Y, Koleske ML, Struckman HL, Mandrioli J, Lou Q, Bonila I, Kim K, Ramos Mondragon R, Priori SG, Volpe P, Valdivia HH, Biskupiak J, Carnes CA, Veeraraghavan R, Györke S, Radwański PB. J Am Heart Assoc. 2020 Jun 2;9(11):e015119. doi: 10.1161/JAHA.119.015119. Epub 2020 May 29.                                                                                                                  

    The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring. Jones AE, King JB, Kim K, Witt DM. J Thromb Thrombolysis. 2020 Oct;50(3):739-745. doi: 10.1007/s11239-020-02064-0.     

                                                   

    Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system. Giannouchos TV, Biskupiak J, Moss MJ, Brixner D, Andreyeva E, Ukert B. Am J Emerg Med. 2021 Feb;40:20-26. doi: 10.1016/j.ajem.2020.12.009. Epub 2020 Dec 9.

     

    Barriers and facilitators of exploiting the potential of value-added medicines. Petykó ZI, Inotai A, Holtorf AP, Brixner D, Kaló Z. Expert Rev Pharmacoecon Outcomes Res. 2020 Apr 23.

                                           

    Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of The Personalized Precision Medicine Special Interest Group. Eric Faulkner, Anke-Peggy Holtorf, Surrey Walton, Christine Y. Liu, Hwee Lin, Eman Biltaj, Diana Brixner, Charles Barr, Jennifer Oberg, Gurmit Shandhu, EMAUD, Uwe Siebert, Susan R. Snyder, Simran Tiwana, John Watkins, Katherine Payne. 2020 April 01.

    Pulleyn T, Kim K, Witt DM, Feehan M, Munger MA. Understanding Patients’ Care Barriers in the Treatment of Venous Thromboembolism. J Thromb Thrombolysis. 2019 Jul;48(1):35-41.

    Bellows BK, Ruiz-Negrón N, Bibbins-Domingo K, King JB, Pletcher MJ, Moran AE, Fontil VClinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals. Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005624. Epub 2019 Jun 5.

    Hawkes JE, Mittal M, Davis M, Brixner D. Impact of Online Prescription Management Systems on Biologic Treatment Initiation. Adv Ther. 2019 Jun 5. [Epub ahead of print]

    Ruiz-Negrón N, Menon J, King JB, Ma J, Bellows BK. Cost-Effectiveness of Treatment Options for Neuropathic Pain: A Systematic Review. Pharmacoeconomics. 2019 May;37(5):669-688.

    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 May 11:1-11. [Epub ahead of print]

    Kim KUnni SBrixner D, Thomas SM, Olsen CJ, Sterling KL, Mitchell M, McAdam-Marx C. Longitudinal Changes in Glycated Haemoglobin Following Treatment Intensification After Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2019 Mar 7. [Epub ahead of print]

    Kim KUnni S, McAdam-Marx C, Thomas SM, Sterling KL, Olsen CJ, Johnstone B, Mitchell M, Brixner D. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents. J Manag Care Spec Pharm. 2019 Mar;25(3):314-322.

    Ruiz-Negrón N, Wander C, McAdam-Marx C, Pesa J, Bailey RA, Bellows BK. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis. J Manag Care Spec Pharm. 2019 Mar;25(3):304-313.

    Brixner DOderda GBiskupiak J, Burgoyne DS, Avey SG, Feldman SR. The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. Am Health Drug Benefits. 2019 Feb;12(1):22-26.

    Chang ANelson RBrixner D. Advancing Pharmacy Practice by Reducing Gaps in Pharmacogenetics Education. Am J Health Syst Pharm. 2019 Feb 9;76(5):320-326.

    Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD. Cost-Effectiveness of Early Cancer Surveillance for Patients with Li-Fraumeni Syndrome. Pediatr Blood Cancer. 2019 Feb 4:e27629.

    Brixner D, Woodward T C, Seifter N, Biskupiak J, Marciniak M, Neumann P, Oderda G. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies. J Manag Care Spec Pharm, 2019 Feb;25(2):164-173.

    Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks N, Cyr P, Taylor SD. Clinical and Economic Outcomes Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-Bolus Insulin (MDI) Therapy: A Retrospective Cohort Study. Clin Ther. 2019 Jan 29. [Epub ahead of print]

    Stenehjem DDAu TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, Brixner DI. Immunotargeted Therapy in Melanoma: Patient, Provider Preferences, and Willingness to Pay at an Academic Cancer Center. Melanoma Res. 2019 Jan 25. [Epub ahead of print].

    Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N. Predictive Genomic Markers of Response to VEGF Targeted Therapy in Metastatic Renal Cell Carcinoma. PLoS One. 2019 Jan 25;14(1):e0210415.

    Tak C, Gunning K, Kim K, Sherwin CM, Ruble JH, Nickman NA, Biskupiak JE. The Effect of a Prescription Order Requirement for Pharmacist-Administered Vaccination on Herpes Zoster Vaccination Rates. Vaccine. 2019 Jan 21;37(4):631-636.

    • Kim K, Magness J, Nelson R, Baron V, Brixner D. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients. J Manag Care Spec Pharm, 2018 Dec;24(12):1250-1259.
    • Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Németh B, Maniadakis N, Brixner D, Wijaya K, Kaló Z. Guidance Toward the Implementation of Multicriteria Decision Analysis Framework in Developing Countries. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592.
    • Mistry R, Suri G, Young K, Hettle R, May JR, Brixner DOderda GBiskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA. Budget Impact of Including Ribociclib in Combination with Letrozole on US Payer Formulary: First-line Treatment of Post-Menopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer. Curr Med Res Opin. 2018 Aug 17:1-8. [Epub ahead of print]
    • Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim KBrixner DI. The Potential Impact of Monitoring Disease Activity Biomarkers on Rheumatoid Arthritis Outcomes and Costs. Personalized Medicine. Per Med. 2018 Jul 1;15(4):291-301.
    • Rohit Mistry, Jessica R. May, Gaurav Suri, Kate Young, Diana BrixnerGary OderdaJoseph Biskupiak, Derek Tang, Subrata Bhattacharyya, Dinesh Mishra, Devarshi Bhattacharyya, Anand A. Dalal. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. J Manag Care Spec Pharm. 2018 Jun;24(6):514-523.
    • Brixner D, Kaló Z, Maniadakis N, Kim K, Wijaya K. An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for health technology Assessment in Emerging Markets. Value Health Reg Issues. 2018 Mar 29;16:9-13.
    • Stenehjem DAu TSainski AMBauer H, Brown K, Lancaster J, Stevens V, Brixner DI. Impact of a Genetic Counseling Requirement Prior to Genetic Testing. BMC Health Serv Res. 2018 Mar 7;18(1):165.
    • Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, Brixner DI, Garrison LP, Murray MD. Nine Years of Comparative Effectiveness Research Education and Training: Initiative Supported by the PhRMA Foundation. J Comp Eff Res. 2018 Feb;7(2):167-175.
    • Unni S, Wittbrodt E, Ma JSchauerhamer M, Hurd J, Ruiz-Negrón NMcAdam-Marx C. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Feb;20(2):468-473.

     

     

     

    • Nelson RE, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, LaFleur J. Predicting discontinuation of pegylated interferon as a result of lack of efficacy in United States Veterans with chronic hepatitis C on dual therapy. Annals of Pharmacotherapy. 2014; In Press.
    • LaFleur J, Hoop R, Korner E, DuVall S, Mortan T, Pandya P, Knippenberg K, and Nelson RE. Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. Gastroenterology Nursing. 2014; In Press.
    • Willson T, Nelson S, Newbold J, Nelson RE, LaFleur J. The clinical epidemiology of male osteoporosis: A review of the recent literature. Clinical Epidemiology. 2014; In Press.
    • Nelson SD, LaFleur J, Hunter E, Archer M, Steinvoort C, Madden C, Oderda G. Clinically meaningful drug-drug interactions: Examples from the Utah Medicaid Drug Regimen Review Center. Journal of Pharmacy Practice. 2014; In Press.
    • Nelson SD, Nelson RE, Cannon GW, Lawrence P, Battistone MJ, Grotzke M, Rosenblum Y, LaFleur J. Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.Osteoporosis International. 2014; In Press.
    • McAdam-Marx C, Bellows BK, Unni S, Wygant G, Mukherjee J, Ye X, Brixner DI. Impact of Adherence and Weight Loss on Glycemic Control in Patients with Type 2 Diabetes: Cohort Analyses of Integrated Medical Record, Pharmacy Claims, and Patient-Reported Data. J Manage Care Pharm. 2014; Accepted for publication.
    • Stenehjem DD, Yoo M, Unni S, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI.  Assessment of single-institution HER2 testing patterns, rate of HER2+ disease and utilization of trastuzumab in early breast cancer.  Breast Cancer: Targets and Therapy. 2014.  Accepted.  In press.
    • LaFleur J, Hoop R, Morgan T, Pandya P, Korner E, Knippenberg K, Hayden C, DuVall S, Nelson R. High rates of early treatment discontinuation in HCV-infected US veterans. BMC Research Notes. 2014; 7(1):266.
    • Bellows BK, LaFleur J, Kamauu A, Ginter T, Forbush TB, Agbor S, DuVall SL. Automated identification of patients with binge-eating disorder from narrative electronic health records. Journal of the American Medical Informatics Association. 2014;21:e1 e163-e168.
    • Stenehjem DD, Albright FS, Kuo K-L, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI.  Response Monitoring, Tolerability and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database. J Natl Compr Canc Netw. 2014;12(8):1113–1121.
    • Buu J, Mullin S, McAdam-Marx C, Solomon M, and Jennings BT.  Identifying Barriers to Influenza Vaccination Recommendation Adherence in an Academic Outpatient Primary Care Clinic Setting. Innov Pharm. 2014; 5(3): Article 4.
    • Shane-McWhorter L, Lenert L, Petersen M, Woolsey S, McAdam-Marx C, Coursey J, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L. The Utah Remote Monitoring Project: Improving Health Care One Patient at a Time. Diab Tech  & Ther. 2014; 16(10). Epub ahead of print.
    • LaFleur J, Hoop R, Korner E, DuVall S, Mortan T, Pandya P, Knippenberg K, and Nelson RE. Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. Gastroenterology Nursing. 2014; In Press.
    • Bellows BK, Kuo KL, Biltaji E, Singhal M, Jiao T, Cheng Y, McAdam-Marx C. Real-world evidence in pain research: A review of data sources. J Pain Palliat Care Pharmacother. 2014 Aug 19. Epub ahead of print
    • McAdam-Marx C, Bellows BK, Unni S, Mukherjee J, Wygant G, Iloeje U, Liberman JN, Ye X, Bloom FJ, Brixner DI. Determinants of Glycemic Control in a Practice Setting: The Role of Weight Loss and Treatment Adherence (The DELTA Study). Int J Clin Pract. 2014; Aug 12. Epub ahead of print.
    • Cai B, McAdam-Marx C. The Determinants of antihypertensive use and expenditure inpatients with hypertension in the United States.  Journal of Pharmaceutical Health Services Research. 2014. Accepted for publication Sept 30, 2013.
    • Munger M, Ruble J, Nelson S, Ranker L, Petty R, Silverstein S, Barton E, Feehan M. National Evaluation of Prescriber Drug Dispensing. Pharmacotherapy. 2014 Jul 23. [Epub ahead of print]
    • Yoo M, Cheng Y, Rhien TJ, Biskupiak J. Current issues in comparative effectiveness research for hepatitis C. DovePress. June 2014; 2014(4):13-27.
    • Bellows BK, LaFleur J, Kamauu A, Ginter T, Forbush TB, Agbor S, DuVall SL. Automated identification of patients with binge-eating disorder from narrative electronic health records. Journal of the American Medical Informatics Association. 2014 Feb; 21(e1):e163-8.
    • Gilreath JA, Stenehjem D, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014 Feb; 89(2):203–212.
    • Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U. Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. Leuk Lymphoma. 2014 Feb 6. [Epub ahead of print]
    • Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. Appl Health Econ Health Policy. 2014 Jan 3. [Epub ahead of print]
    • McAdam-Marx C, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U,Brixner DI. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract. 2014; 103(3):402-11

     

    • Nelson RE, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, LaFleur J. Pegylated-interferon discontinuation due to lack of efficacy in United States veterans with chronic hepatitis C. Annals of Pharmacotherapy. 2013; In Press.
    • Saverno K, Gothe H, Schuessel K, Biskupiak JE, Schulz M, Siebert U,Brixner DI. Consideration of International Generic Distribution Policies on Patient Outcomes in the United States and GermanyDie Pharmazie. 2013. In Press.
    • Brixner DI, Malone D, Hines L, Tang D, Warholak T, Taylor A. (2013) Evaluation of Pharmacy and Therapeutic (P & T) Committee Member Knowledge, Attitudes and Ability Regarding the Use of Comparative Effectiveness Research (CER) in Health Care Decision-Making. Research in Social & Administrative Pharmacy. 2013 Dec 3. [Epub ahead of print]
    • Nelson RE, Stenehjem D, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer. 2013 Dec; 82(3):461-8.
    • Biskupiak J, Ghate SR, Jiao T, Brixner D. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm. 2013 Nov-Dec; 19(9):789-98.
    • Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, Hurwitz J, Brixner D, Malone DC. Health care decision makers' use of comparative effectiveness research: report from a series of focus groups. J Manag Care Pharm. 2013 Nov-Dec; 19(9):745-54.
    • Nelson S, Munger M. Icosapent Ethyl for Treatment of Elevated Triglyceride Levels: A Review of the Literature. Ann Pharmacother. 2013 Nov: 47(11):1517-2.
    • Smelick GS, Heffron TP, Chu L, Dean B, West DA, DuVall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development. Mol Pharm. 2013 Oct. [Epub ahead of print]
    • Blouin R. Brixner DI, Cutler S. Derendorf HC, Poloyak SM, Ellingrod Ringold VL, Schnellman RG, Swaan P, Lau YS. The Report of the 2012-2013 Research and Graduate Affairs Committee. Am J Pharm Educ. 2013 Oct; 77(8):s9.
    • Ferraro JP, Daumé H 3rd, DuVall SL, Chapman WW, Harkema H, Haug PJ. Improving performance of natural language processing part-of-speech tagging on clinical narratives through domain adaptation. J Am Med Inform Assoc. 2013 Sep-Oct; 20(5):931-9.
    • Robinson M, Gunning K, Pippitt K, McAdam-Marx C, Jennings BT. Team-based approach to addressing simvastatin safety concerns. J Am Pharm Assoc. 2013 Sep-Oct; 53(5):539-44.
    • Stevens V, van Wijngaarden E. Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection. Evid Based Med. 2013 Oct; 18(5):193-4.
    • Oottamasathien S, Jia W, Roundy LM, Zhang J, Wang L, Ye X, Hill AC, Savage J, Lee WY, Hannon AM, Milner S, Prestwich GD. Physiologic Relevance of LL-37 Induced Bladder Inflammation and Mast Cells.Journal of Urology. 2013 Oct; 190(4 Suppl):1596-602.
    • Stevens V, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G.  Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect. 2013 Sep. [Epub ahead of print]
    • Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, Celli B, Tesfaigzi Y. Rapid Lung Function Decline in Smokers is a Risk Factor for COPD and is Attenuated by ACE Inhibitor Use. Chest. 2013 Sep 5. [Epub ahead of print]
    • Nelson RE, Battistone MJ, Ashworth WD, Barker AM, Grotzke M, Huhtala TA, LaFleur J, Tashjian RZ, Cannon GW. Cost effectiveness of training rural providers to perform joint injections. Arthritis Care and Research. 2013 Sep 19. [Epub ahead of print]
    • Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said Q. Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract. 2013 Sep;19(5):360-74.
    • Goodman MJ, Ghate SR, Mavros P, Sen S, Marcus RL, Joy E, Brixner DI. Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004. J Cachexia Sarcopenia Muscle. 2013 Sep; 4(3):187-97.
    • Cai B, Nickman N, Gaffney D.  The cost–effectiveness of external beam radiation therapy in bone metastases. Curr Opin Support Palliat Care. 2013 Sep; 7(3): 278-283.
    • Roundy L, Jia W, Zhang J, Ye X, Prestwich G and Oottamasathien S. LL-37 induced cystitis and the receptor for advanced glycation end-products (RAGE) pathway. Advances in Bioscience and Biotechnology. 2013 Aug. 4; 1-8.
    • Khadem T, Stevens V. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review. [Review]. J Pain Palliat Care Pharmacother. 2013 Aug; 27 (3), 268-83.
    • Kirkness CS, McAdam-Marx C, Unni SYoung JYe X, Chandran A, Peters CL, Asche CV. Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. J Pain Palliat Care Pharmacother. 2013 Aug; 27(3):235-43.
    • Young JNickman NA, Biskupiak JE, Barney RB, Gaffney DK, Namjoshi M, Brandt P. Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid. Breast. 2013 Aug; 22(4):495-503.
    • Ren J, Ning Z, Asche CV, Zhuang M, Kirkness CS, Ye X, Fu J, Pan Q. Trends and predictors in methadone maintenance treatment dropout in Shanghai, China: 2005-2011. Curr Med Res Opin. 2013 Jul; 29(7):731-8.
    • McAdam Marx C. Economic implications of type 2 diabetes management. Am J Manag Care. 2013 Jun; 19(8 Suppl):S143-8.
    • Brixner DI, Bron M, Bellows BK, Ye X, Yu J, Raparla S, Oderda GM. Evaluation of cardiovascular risk factors, events, and costs across four BMI categories. Obesity (Silver Spring). 2013 Jun; 21(6):1284-92.
    • Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013 Jun; 27(2):167-75.
    • Stanford JB, Martin JC, Gibson M, Birdsall E, Brixner DI. Use of clomiphene citrate in the University of Utah Community Clinics. J Reprod Med. 2013 May-Jun; 58(5-6):229-33.
    • Goodman MJ, Brixner DI. New therapies for treating Down syndrome require quality of life measurement. Am J Med Genet A. 2013 Apr; 161A(4):639-41.
    • Lin J, Jiao T, Biskupiak JE, McAdam-Marx C. Application of electronic medical record data for health outcomes research: a review of recent literature. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr; 13(2):191-200.
    • Stevens V, Concannon C, van Wijngaarden E, McGregor J. Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated clostridium difficile infection (CDI) within a retrospective cohort. BMC Infect Dis, 2013 Mar; 13(1), 150.
    • Garg V, Shen X, Cheng Y, Nawarskas JJ, Raisch DW. Use of number needed to treat in cost-effectiveness analyses. Ann Pharmacother. 2013 Mar; 47(3):380-7.
    • Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI.Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health. 2013 Mar; 52(3):336-43.
    • Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother. 2013 Mar; 27(1):62-70
    • Ghate S, Porucznik C, Said Q, Hashibe M, Joy E, Brixner DI. Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. Journal of Adolescent Health. 2013 Mar; 52(3):336-43.
    • Cai B, Nickman NA, Gaffney DG. The Role of Palliative External Beam Radiation Therapy (EBRT). Bone Metastases Pain Management. 2013 Mar; 27(1):28-34.
    • Talal A, LaFleur J, Hoop RS, Pandya P, Martin P, Jacobson I, Han J, Korner E. Absolute and relative contraindications to pegylated interferon or ribavirin in the US general patient population with chronic hepatitis: Results from US database of over 45,000 patients.Alimentary Pharmacology & Therapeutics 2013 Feb; 37(4):473-81.
    • Chen SY, Lee YC, Alas V, Greene M, Brixner DI. Outcomes Associated with Concordance of Oral Antidiabetic Drug Treatments to Prescribing Information in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Journal of Medical Economics. 2013 Feb; 16(5): 586-95.
    • Raimundo K, Biskupiak J, Goodman M, Silverstein S, Asche C. Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma. J Med Econ. 2013; 16(5):606-13.
    • Nelson RE, Nebeker JR, Hayden C, Reimer L, Kone K, LaFleur J.Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis. AIDS Behav. 2013 Jan; 17(1):160-7.
    • Holtorf A, Brixner DI, Bellows B, Keskinaslan A, Dye J, Oderda G. (2012) Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. American Health and Drug Benefits Nov/Dec 2012: 5(7): 428-438.
    • Ghate S, Porucznik C, Said Q, Hashibe M, Joy E, Brixner DI. (2012) Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. Journal of Adolescent Health. In Press.
    • Stevens V, van Wijngaarden E. (2012). Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection. Evid Based Med. (Epub ahead of print).
    • Young, J, Nickman NA, Biskupiak JE, Barney RB, Gaffney DK, Namjoshi M, Brandt P. Characterization of clinical course and usual care patterns in female breast cancer patients treated with zoledronic acid. The Breast 2012; in press.
    • Kirkness CS, McAdam-Marx C, Unni S, Young J, Ye X, Chandran A, Peters CL, Asche CV. Characterization of Patients Undergoing Total Knee Arthroplasty in a Real-World Setting and Pain-Related Medication Prescriptions for Management of Postoperative Pain. J Pain Palliat Care Pharmacother. 2012 Dec;26(4):326-333.
    • Jennings BT, McAdam-Marx C. Implementation of a Pharmacist-Managed Diabetes Program in a Community Clinic-Based Pharmacy Program. Am J Health Syst Pharm. 2012 Nov 15;69(22):1951-3.
    • Nickman NA. Safety of automation technologies in healthcare. J Ergonom 2012. Editorial.
    • McAdam-Marx C. Commentary: Managed Care Pharmacy Perspective in Evaluating Current Modes for Insulin Delivery and Glucose Monitoring in Patients with Diabetes. J Manag Care Pharm. 2012.18(6): S14.
    • McAdam-Marx C, Joy E, Dahal A, Brixner DI. A Retrospective Analysis of Follow-up Timing and Blood Pressure Outcomes after Initiation of Antihypertensive Therapy in Patients with Hypertension Treated in a Utah Community Setting. Accepted for publication, September, 2012. Utah Health 2012.
    • Jones MM, DuVall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Extraction of Methicillin-Resistant Staphylococcus aureus Data from the Nation's Veterans Affairs Medical Centers. BMC Med Inform Decis Mak. Jul 2012, 12:34.
    • Saverno K, Rochau U, Stenehjem D, Morley K, Siebert U, Brixner DI. (2012) Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. Journal of Managed Care Pharmacy. July/August 18(6): 457-463.
    • Brixner DI. (2012) This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? [Introduction] Journal of Managed Care Pharmacy. Suppl, June 18(5):S5.
    • Brixner DI, Watkins J, Oderda G, Sifford-Wilson S, Biskupiak J, Dunn J, Holtorf A, (2012) This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? Journal of Managed Care Pharmacy. Suppl, June 18(5):S6-19.
    • Brixner DI, Oderda G. (2012) [Introduction] Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. Journal of Managed Care Pharmacy. Suppl, May 18:(4a):S3-S4.
    • Brixner DI, Oderda G, Mohr P, Dubois R, Cannon HE. (2012) Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. Journal of Managed Care Pharmacy. Suppl, May 18:(4a):S5-17.
    • Bellows BK, Dahal A, Jiao T, Biskupiak J. (2012) A cost-utility analysis of pregabalin vs. duloxetine for the treatment of painful diabetic neuropathy. Palliat Care Pharmacother. 2012;26(2):153-64. April 18, 2012 [Epub]
    • Goodman M, Durkin M, Forlenza J, Ye X, Brixner DI. (2012) Assessing Adherence-based quality measures in epilepsy. International Journal for Quality in Health Care. April 16, 2012.
    • Garvin JH, DuVall SL, South BR, Bray BE, Bolton D, Heavirland J, Pickard S, Heidenreich P, Shen S, Weir C, Samore M, Goldstein MK. Automated extraction of ejection fraction for quality measurement using regular expressions in Unstructured Information Management Architecture (UIMA) for heart failure. J Am Med Inform Assoc. 2012 Mar 21. [Epub ahead of print]
    • LaFleur J, McAdam-Marx C, White GL, Lyon JL, Oderda GM. Comparing medication adherence methods in lipid-modifying therapy. Journal of Pharmacy Technology. 2012;28(2):58-67.
    • Nelson R, Nebeker J, Hayden C, Reimer L, Kone K, LaFleur J. Adherence to HIV antiretroviral drugs is worse for protease inhibitor (PI)-based regimens than for non-nucleoside reverse transcriptase inhibitor (NNRTI)- based regimens. AIDS and Behavior. 2012; In press.
    • Gilreath JA, Stenehjem DD, Rodgers GM. Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+? J Natl Compr Canc Netw. 2012;10(5):669-676.
    • Marcus RL, Brixner DI, Ghate S, LaStayo P. Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults. Current Gerontology and Geriatrics Research. 2012;2012.
    • Nelson RE, Nebeker JR, Sauer BC, Lafleur J. Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. Bone. Jan 18 2012; 50(4):983-8.
    • Bellows BK, Biskupiak J. Methodological challenges of comparative effectiveness research in pain pharmacotherapy: implications for investigators, clinicians, and policy makers. J Pain Palliat Care Pharmacother. 2011;25(3):267-274.
    • Ram CVS, Ramaswamy K, Quan C, Biskupiak J, Ryan A, Quah R, Russo PA. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: A comparative effectiveness analysis from electron medical record data. Journal of Clinical Hypertension 2011 (in press).
    • McAdam-Marx C, McGarry L, Hane C, Biskupiak J, Deniz B, Brixner D.All-cause and incremental per patient per year cost associated with chronic hepatitis-C and associated liver complications in the United States: A managed care perspective. Journal of Managed Care Pharmacy 2011;17(7):531-546.
    • Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-Cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. Journal of Managed Care Pharmacy 2011;17 (in press).
    • LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: A case study in healthy user bias and hypertension. Heart. 2011: In press.
    • LaFleur J, Nelson RE, Yao Y, Adler R, Nebeker J. Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporosis International. 2011: In press.
    • Nelson RE, McAdam-Marx C, Evans M, LaFleur J. Patent extension policy for pediatric indications: An evaluation of the impact within three drug classes in a state Medicaid program. Applied Health Economics and Health Policy 2011;9(3):171-81.
    • Asche C, LaFleur J, Conner C. Diabetes treatment adherence and the association with economic, clinical, and humanistic outcomes. Clinical Therapeutics. 2011;33(1):74-109.
    • LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, Nebeker J, Brixner DI, Silverman S. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: A historical cohort study using electronic medical record data. Journal of Bone and Mineral Metabolism. 2011;29(2):193.
    • Ghate S, Biskupiak J, Ye X, Hagan M, Kwong W, Fox E, Brixner DI. Hemorrhagic and Thrombotic Events Associated With Generic Substitution of Warfarin in Patients with Diagnosis of Atrial Fibrillation. A Retrospective Analysis. Ann Pharmacotherapy 2011;45:701-12.
    • Raimundo KP, Asche CV. A review of the efficacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi's sarcoma. HIV & AIDS Review. 2011; doi:10.1016/j.hivar.2011.04.002.
    • McAdam-Marx C, Bouchard J, Aagren M, Conner C, Brixner DI. Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. Clin Ther. 2011; 33(1):110-20.
    • Bellows BK, Hunter E, McAdam-Marx C. Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes. Clinical Medicine Reviews in Vascular Health. Libertas Academica. 2011(3).
    • Young JR, McAdam-Marx C. Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog McAdam-Marx, Clinical Medicine Insights: Endocrinology and Diabetes. Libertas Academica. 2010(3).
    • Nickman NA, Haak S, Kim JW. Use of clinical simulation centers in health professions schools for patient-centered research. Simulation in Healthcare October, 2010;5 (5):295-302.
    • Goodman MJ, Nordin JD, Belongia EA, Mullooly JP, Baggs J. Henoch-Sch�lein purpura and polysaccharide meningococcal vaccine. Pediatrics. 2010 Aug;126(2):e325-9. Epub 2010 Jul 12.
    • Yu J, Smith K, Brixner DI. (2010) Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine: A Markov Model Application. CNS Drugs, 24(8).
    • Nickman NA, Haak SW, Kim JW. Cost minimization analysis of different growth hormone pen devices based on time-and-motion simulations. BMC Nursing 2010; 9 (6).
    • McAdam-Marx C, Gaebler JA, Bellows BK, Brixner DI. Comtemporary Management of Patients with Type 2 Diabetes. Exp Rev Cardiovasc Ther. 2010, 8 (6), 767-770.
    • Brixner DI, McAdam-Marx C, Ye X, Lau H, Munger MA. Assessment of Time to Follow-up Visits in Newly-Treated Hypertensive Patients Using an Electronic Medical Record Database. Curr Med Res Opin. 2010 26(8) 1881-91.
    • Ghate S, Haroutiunian S, Winsow R, McAdam-Marx C. Cost and Comorbidities Associated with Opioid Abuse in Managed Care and Medicaid Patients in the United Stated: A Comparison of Two Recently Published Studies. J Pain Palliat Care Pharmacother; 2010 (Accepted for publication.)
    • McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of Opioid Abuse and Misuse Determined from a Medicaid Database. J Pain Palliat Care Pharmacother. 2010; 24(1):5-18.
    • McAdam-Marx C, Yu J, Bouchard J, Aagren M, Brixner DI. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin. 2010 Jan 26; (1):191-201.
    • McAdam-Marx C, Field RT, Metraux S, Moelter ST, Brixner DI. Physician Utilization by Insurance Type in Youth with Type 2 Diabetes, Am J Manag Care. 2010; 16(1):55-64.
    • Said Q, McAdam Marx C, Schwartz SJ, Ben-Joseph R, Brixner DI. Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over Five Years or More. Value in Health, 2010; 13(2):265-272.
    • McAdam-Marx C, Bouchard J, Aagren M, Nelson R, Brixner D. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes Obes Metab. 2010; 12(1):54-64.
    • Carl V. Asche, Ph.D., Laura Shane-McWhorter, Pharm.D., B.C.P.S., F.A.S.C.P., B.C.-A.D.M., C.D.E., Swetha Raparla, M.S. Health Economics and Compliance of Vial/Syringe Versus Pen Devices: A Review of the Evidence. Diabetes Technology & Therapeutics, 2010;12 (Suppl 1).
    • Yu J, Goodman MJ, Oderda GM. Economic evaluation of pharmacotherapy of migraine pain: a review of the literature. J Pain Palliat Care Pharmacother. 2009 Dec; 23(4):396-408.
    • Said Q, Marx CM, Schwartz JS, Ben-Joseph R, Brixner DI. (2009). Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More. Value Health October 2009.
    • Asche C. "ISPOR International Digest of Databases" International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections, September/October, 2009.
    • Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporosis International. 2009 Oct 2. [Epub ahead of print]
    • McAdam-Marx C, Brixner DI, Metraux S, Moelter S, Field R. Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting. Diabetes 2009; 58(S1):A514.
    • Brixner D, McAdam-Marx C, Nelson R, Aagren M, Bouchard J. Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting. Diabetes 2009; 58(S1):A514.
    • McAdam-Marx C, Brixner DI, Ye X, Misurski D, Fabunmi R. A1C Outcomes at 6 and 18 Months in Insulin Na�ve Patients with Type 2 Diabetes Treated with Analog Basal Insulin in an Ambulatory Care Setting. Diabetes 2009; 58(S1):A513.
    • Smith MD, Drummond M, Brixner D. (2009). Moving the QALY forward: rationale for change. Value Health, 12 Suppl 1, S1-4.
    • McAdam-Marx C, Fabunmi R, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Brixner DI. A1C and Weight outcomes at 18 months in patients with type 2 diabetes treated with Exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism. 2009 Dec; 11(12):1173-4.
    • McAdam-Marx C, Bouchard J, Aagren M, Nelson R, Brixner D.Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes, Obesity and Metabolism. 2009 Sep 16. [Epub ahead of print]
    • Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism. 2009 Dec; 11(12):1122-30.
    • Asche C. Use of Patient Registry Data in Evaluating Patient Reported Outcomes. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections, July/August, 2009.
    • Said Q, McAdam Marx C, Schwartz SJ, Ben-Joseph R, Brixner DI.Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over Five Years or More. Value in Health. 2009 (in press).
    • LaFleur J. Osteoporosis: "Need-to-knows" for pharmacists about bone health. Pharmacy Times. June 2009; (In press).
    • Kane SV, Accortt NA, Magowan S, Brixner D. (2009). Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther, 29(8), 855-62.
    • Brixner DI, Holtorf AP, Neumann PJ, Malone DC, Watkins JB. (2009). Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm, 15(3), 275-83.
    • McAdam-Marx C. Ye X, Sung JC, Brixner DI, Kahler KH. Results of a Retrospective, Observational Pilot Study Using Electronic Medical Records to Assess the Prevalence and Characteristics of Patients with Resistant Hypertension in an Ambulatory-Care Setting. Clinical Therapeutics. 2009; 31(5):1116-23.
    • LaFleur J, Larsen B, Madden C, Gunning K, Stoddard GJ, Oderda L, Steinvoort C, Oderda G. Agreement between pharmacists for problem-identification: An initial quality measurement of cognitive services. Annals of Pharmacotherapy. 2009; 43(7):1173-80.
    • Holtorf AP, McAdam-Marx C, Schaaf D, Eng B, Oderda G. Systematic review on quality control for drug management programs: Is quality reported in the literature? BMC Health Services Research. 2009; 9(1):38.
    • Yu J, Brixner DI, Ghate SR, Gondor K. A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. Utah's Health: An Annual Review IX. 2009.
    • McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Prevalence and Characteristics of Patients with Resistant Hypertension in an Ambulatory Care Setting. Clinical Therapeutics. 2009, 31(5), 1116-1123.
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. (2008) Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging. 2008;25(7):611-22
    • Kirkness CS, Yu J, Asche CV. The Effect on Comorbidity and Pain in Patients with Osteoarthritis. J Pain Palliat Care Pharmacother. 2008; 22(4) 336 � 48.
    • Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. (2008) Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. Sep;24(9):2597-607.
    • Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. (2008) Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2008 Aug;10(8):638-45. Epub 2007 Jul 21.
    • Kirkness CS, Marcus RL, Lastayo PC, Asche CV, Fritz JM. (2008) Diabetes and associated risk factors in patients referred for physical therapy in a national primary care electronic medical record database. Phys Ther. 2008 Nov; 88(11):1408-16. Epub 2008 Sep 18.
    • McAdam-Marx C, Schaaf D, Holtorf AP, Eng B, Oderda G. (2008) Systematic Analysis of Outcomes Evaluations Applied to Drug Management Programs. American Journal of Managed Care, Suppl. Nov;14(11 Suppl):SP36-45.
    • Asche CV, Nelson RE. The benefits and risks of new therapies for type 2 diabetes. J Manag Care Pharm. 2008 Sep;14(7):655-7. Review.
    • Asche CV, McAdam-Marx C, Seal B, Crookston B, Mullins CD. (2008) Treatment Costs Associated with Community-Acquired Pneumonia by Community Level of Antimicrobial Resistance. Journal of Antimicrobial Chemotherapy (JAC). May; 61(5):1162-8. Epub 2008 Feb 29.
    • Asche C, Said Q, Joish V, Hall CO, Brixner DI. (2008). Assessment of COPD-related outcomes via a national electronic medical record database. International Journal of COPD, 3(2): 323-6.
    • Asche C, McAdam-Marx C, Shane-McWhorter L, Plauschinat C. (2008) Adverse Events and Oral Antidiabetic Outcomes Among Seniors in a Real World Setting. Drugs and Aging. 25(7):611-622.
    • Brixner DI, McAdam-Marx C. (2008) Cost-Effectiveness of Insulin Analogs. The American Journal of Managed Care. Nov; 14(11): 766-75.
    • Brixner DI, Ghate SR, McAdam-Marx C, Ben-Joseph R, Said Q.(2008). Association between cardiometabolic risk factors and body mass index on diagnosis and treatment codes in an electronic medical record database. J Manag Care Pharm, Oct; 14(8): 756-67. (Nominated as 1 of 15 articles by JMCP Editorial Advisory Board for 2008 JMCP Award of Excellence)
    • Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. (2008) Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. Aug;30(8):1558-63.
    • Hendlish SK, Horowicz-Mehler NC, Brixner DI, Stern LS, Doyle JJ, Chang J, Hagan M. (2008) Contraceptive and noncontraceptive benefits of the LNG-IUS in a vertically integrated HMO. Contraception. 2008 Jul;78(1):36-41. Epub 2008 May 14.
    • LaFleur J, McAdam-Marx C, Kirkness C, Brixner DI. (2008). Clinical risk factors for fracture in post-menopausal osteoporotic women: a review of the recent literature. Ann Pharmacother, 42(3): 375-86. Epub 2008 Jan 29. Review.
    • Murphy PA, Brixner DI. (2008). Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception, Apr; 77(4):257-63.
    • Holtorf AP, Watkins JB, Mullins CD, Brixner DI. Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. Journal of Managed Care Pharmacy: JMCP, 2008, 14(3), 302-8.
    • Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, Brixner DI.Somnolence effects of antipsychotic medications and the risk of unintentional injury. Pharmacoepidemiol Drug Saf. 2008 Mar 4. [Epub ahead of print]
    • Kane SV, Brixner DI, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008 Jan;14(1 Suppl A):s2-12; quiz s13-5.
    • Merrill RM, Layman AP, Oderda G, Asche CV. Risk Estimates of Hysterectomy and Selected Conditions Commonly Treated with Hysterectomy. Annals of Epidemiology, 2008 Mar; 18(3): 253-60.
    • Muszbek N, Brixner DI, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008 Feb;62(2):338-51.
    • Asche CV.Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: Results of a small survey of managed care organizations and pharmaceutical manufacturers. Commentary on the article by Nichols MB et al. J Manag Care Pharm. 2007 May;13(4):360-71.
    • Oderda GM, Said Q, Evans RS, Stoddard GJ, Lloyd J, Jackson K, Rublee D, Samore MH. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007 Mar;41(3):400-6. Epub 2007 Mar 6.
    • LaFleur J, Said Q, McAdam-Marx C, Jackson K, Mortazavi M. The problems of studying the association between race and pain in outcomes research. J Pain Palliat Care Pharmacother. 2007;21(3):57-62.
    • Asche CV, Kirkness C, McAdam-Marx C, Fritz J. The societal costs of low back pain A Review of Studies Published Between 2001 and 2007. J Pain Palliat Care Pharmacother. 2007;21(4):25-33.
    • Nickman NA, Biskupiak J, Creekmore F, Shah H, Brixner DI. Antiplatelet medication management in patients hospitalized with ischemic stroke. Am J Health Syst Pharm. 2007 Nov 1;64(21):2250-6.
    • Brixner DI, Rubin DT, Sewitch MJ. The Complexity of Compliance and Persistence in Ulcerative Colitis. Gastroenterology and Hepatology. 3(Suppl. 9) S1-10.
    • Asche C, Kirkness C, McAdam-Marx C, Fritz J. The societal costs of low back pain: A Review of Studies Published Between 2001 and 2007. Journal of Pain and Palliative Care Pharmacotherapy, 2007, December, 21 (4).
    • Asche C, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat C. Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting. Diabetes Obes Metab. 2007 Jul 21.
    • Brixner DI. Prevalence and burden of migraine and the impact on managed care. Manag Care. 2007 Jul;16 (7 Suppl 7):2-3; discussion 15-7.
    • Brixner DI. Prevalence and burden of migraine and the impact on managed care. Currents: Pain Management News and Research, E-Newslatter of the American Academy of Pain Management. Nov. 2007.
    • Nickman NA, Biskupiak J, Creekmore F, Shah H, Brixner DI.Antiplatelet medication management in patients hospitalized with ischemic stroke. Am J Health Syst Pharm. 2007; Nov 64(21):2250-6.
    • Brixner DI, Lenhart G, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. Current Medical Research and Opinion. 2007; Nov 23(11):2887-95.
    • McAdam-Marx C, LaFleur, J, Kirkness C, Asche CV. Postmenopausal osteoporosis: current and future treatment options. P&T, 2007; 32(7):392-402.
    • Oderda G, Asche CV, Jones K, Merrill R, Spalding J. Characterization of Therapy and Costs for Patients with Uterine Fibroids in Utah Medicaid. Archives of Gynecology and Obstetrics, 2007; 276(3):211-8. Epub Mar 7.
    • Brooks T, Creekmore F, Young D, Asche CV, Oberg B, Samuelson W. Hospitalization and Emergency Room Visit Rates in Asthma and Chronic Pulmonary Disease Patients Taking Beta-Blockers. Pharmacotherapy, 2007; 27(5):684-690.
    • Wick J, LaFleur J. Fatigue: Implications in the elderly. The Consultant Pharmacist. 2007; 22(7):566-78.
    • Holtorf AP, LaFleur J, Servatius D, Jeffries B, McBeth C, Brixner DI.Statin treatment of diabetic patients in Utah Medicaid. Utah's Health: An Annual Review, 2007; 12(Supplement):57-71.
    • Holtorf AP, LaFleur J, Servatius D, Jeffries B, Brixner DI. Prescription drug use by women and men in Utah Medicaid. Utah's Health: An Annual Review, 2007; 12(Supplement):97-99.
    • Tuteja AK, Biskupiak JE. Chronic Constipation: Overview and Treatment Options. P&T, 2007; 32(2):91-105.
    • Brixner DI, Joish V, Oderda GM, Avey S, Hanson D, Cannon HE. Effects of Benefit Change Across 5 Disease States. The American Journal of Managed Care, 2007; 13(6 pt 2):370-6.
    • Jackson K, Nahoopii R, Said Q, Dirani R, Brixner DI. An Employer-Based Cost Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation. Journal of Occupational and Environmental Medicine, 2007; 49(4): 453-60.
    • Ho MJ, Kirkness C, Brixner DI (2007) Problem Based Learning in Pharmacy Management. Journal of Pharmacy Teaching, 49(4), 453-60.
    • Brixner DI, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G.Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. Value Health, 2007; 10(Suppl 1):S29-36.
    • Brixner DI, Miller P, Fox J, Calabrese D, Tangalos E, Gruber J, Skinner N. The Role of Observational Data in Clinical Decision-Making for Osteoporosis: Commentaries from Managed Care and Senior Care [C.E. Program]. Hotwire for Managed Markets, April 2007.
    • Asche CV, Seal B, Jackson K, Oderda GM. Economic evaluations in pain management: Principles and Methods. Journal of Pain and Palliative Care Pharmacotherapy, 2006; 20(3).
    • Maio V, Yuen EJ, Smith KD, Brixner DI, Oderda GM, Asche CV, Morgan S. Multi-national assessment of outcomes via retrospective database. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections, 2006; 12(4).
    • Jackson KC. Pharmacotherapy for neuropathic pain. Pain Pract. 2006 Mar;6(1):27-33. Review.
    • Brixner DI. The case against excessive cost sharing. American Journal of Managed Care, 2006; 12(6 Suppl):S162-4.
    • Brixner DI, Oderda GM, Nickman NA, Beveridge R, Vermulen L, Jorgenson J. Documentation of chemotherapy infusion preparation costs in academic and community-based oncology practices. Journal of the National Comprehensive Cancer Network, 2006; 4(3):197-208.
    • Brixner DI, Oderda GM, Roland CL, Rublee DA. Opioid expenditures and utilization in the Medicaid system. Journal of Pain and Palliative Care Pharmacotherapy, 2006; 20(1):5-13.
    • Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, Oderda GM. Naturalistic impact of second-generation antipsychotics on weight gain. The Annals of Pharmacotherapy, 2006; 40(4):626-32. Epub 2006Mar 28.
    • LaFleur J, McBeth C, Gunning K, Oderda L, Steinvoort C, Oderda GM.A Pharmacist-Run Drug Regimen Review Center: Prevalence of Drug-Related Problems among Medicaid High Utilizers. Journal of Managed-Care Pharmacy; 2006; 12(8):677-85.
    • LaFleur J, Thompson C, Joish VN, Charland SL, Oderda GM, Brixner DI. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Annals of Pharmacotherapy, 2006; 40(7-8):1274-9.
    • Sbarbaro J, Nicolau D, Asche CV. Management of community-acquired respiratory tract infections in an era of increasing antibiotic resistance. Pharmacy and Therapeutics, 2006; 31(5):106-111.
    • Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal anti-inflammatory drugs. J Pain Palliat Care Pharmacother, 2006; 20(3):7-14.
    • Joish VN, Brady E, Stockdale WA, Brixner DI, Dirani R. Evaluating diagnosis and treatment patterns of COPD in primary care. Treatments in Respiratory Medicine, 2006; 5(4):283-93.
    • Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and Economic Implications of Heparin-Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism. Pharmacotherapy, 2006; 26(10):1438-45.
    • Brixner DI. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Managed Care, 2006; 12(Suppl 7):S191-8; Erratum in Am J Manag Care, 2006; 12(7):370.
    • Asche CV. Outcomes and economics in pain and palliative care Explicit mention of outcomes in prescribing information. Journal of Pain and Palliative Care Pharmacotherapy, 2005; 19(2):45-47.
    • Asche CV, Oderda G, Brixner D. Has the cost-effectiveness of Xolair� (omalizumab) been underestimated? The Journal of Allergy and Clinical Immunology, 2005; 15(5):1095. Author reply 1095-6.
    • Biskupiak, JE, Korner E. Assessing the value of hospice care: Is documentation of cast savings necessary? Journal of Pain and Palliative Care Pharmacotherapy, 2005; 19(4):61-5.
    • Brixner DI. Improving acute otitis media outcomes through proper antibiotic use and adherence. The American Journal of Managed Car, 2005; 11(6Suppl):S201-10.
    • Brixner DI. Managing the continuum of treatment: modeling the economic impact of treating Diabetes. Journal of Managed Care Pharmacy, 2005; 11(6, S-b):S19-S22.
    • Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. American Journal of Managed Care, 2005; 11(15Suppl):S459-64.
    • Gerbino PP, Brixner DI, Sbarbaro J, Nicolau D. Appropriate antibiotic therapy for community-acquired respiratory tract infections. Managed Care Interface, 2005; 18(12):41-8.
    • Halpern MT, Schmier JK, Snyder LM, Asche CV, Sarocco P, Nieman R, Lavin B, Mandell L. Meta-analysis of anti-microbial failure. Journal of Antimicrobial Chemotherapy, 2005; 55(5):748-57.
    • Ho MJ, Joish VN, Biskupiak J. The role of pharmacoeconomics in formulary management: Triptan Case Study for Migraine. Pharmacy and Therapeutics, 2005; 30(1):36-46.
    • Joish VN, Oderda GM. Understanding cost-utility analysis and its application. Journal of Pain and Palliative Care Pharmacotherapy, 2005; 19(1):57-61.
    • Joish VN, Malone DC, Wendel C, Draugalis JR, Mohler MJ. Development and validation of a diabetes severity index (DSI) LA risk adjustment tool for predicting healthcare resource use and costs. Pharmacotherapy, 2005; 25(5):676-84.
    • Joish VN, Donaldson G, Stockdale WA, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, Brixner DI. Economic impact of GERD and PUD: examination of direct and indirect costs due to worker absenteeism using a large integrated patient database. Current Medical Research and Opinion, 2005; 21(4):535-44.
    • LaFleur J. Evaluating the Relationship between treatment and costs-Measuring the atom with a yard-stick? Journal of Managed Care Pharmacy, 2005; 11(7):588-589.
    • LaFleur J, Thompson C, Ho M, Stockdale W, Charland SL, Oderda G, Brixner DI. Cost analysis of combination vs. single dosage lipid lowering. Hospital Formulary, 2005; 40(7):233-234.
    • McWhorter L, Oderda GM. Providing diabetes education and care to underserved patients in a collaborative practice at the Utah community health center. Pharmacotherapy, 2005; 25(1):96-109.
    • Sullivan PW, Valuck R, Brixner DI, Armstrong EP. A pharmacoeconomic model for making value-based decisions about serotonin reuptake inhibitors. Pharmacy and Therapeutics, 2005; 30(2):96-106.
    • Trost LF III, Wender RC, Suter CC, Rosenberg JH, Brixner DI, Von Worley AM, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Diagnosis guidelines. Postgraduate Medicine, 2005; 118(6):22-6.
    • Trost LF III, Wender RC, Suter CC, Von Worley AM, Brixner DI, Rosenberg JH, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Treatment guidelines. Postgraduate Medicine, 2005; 118(6):29-33.
    • Brandes JL, Brixner DI. Migraine Matters: The role of triptans in relieving the burden in management care. Journal of Managed Care Pharmacy, 2004; 10(4, S-b):S2-12.
    • Briggs DD, Brixner DI, Cannon HE, George DL. Overview of chronic obstructive pulmonary disease: new approaches to patient management in managed care systems. Journal of Managed Care Pharmacy, 2004; 10(4, S-a):S2-10.
    • Brixner DI. Clinical and economic outcomes in the treatment of lower respiratory tract infections. The American Journal of Managed Care, 2004; 10(12):S400-407.
    • Brixner DI. Standardizing managed care formulary submissions: the AMCP format. Managed Care, 2004; 13(5):14-17.
    • Gunter MJ, Worley AV, Carter S, Gregory C, Brixner DI. Impact of a seizure disorder disease management program on patient-reported quality of life. Disease Management Journal, 2004; 7(4):333-347.
    • Ho MJ, Biskupiak J. Would Depression Management Relieve Pain and Improve Function? Journal of Pain and Palliative Care Pharmacotherapy, 2004; 18(4):81-87.
    • Ho MJ, Joish VN, LaFleur J, Christensen RL, Brixner DI.Pharmacoeconomic Analysis of Oral Triptans. Formulary, 2004; 39:356-357.
    • Ho MJ, LaFleur J. The Treatment Outcomes of Pain Survey (TOPS): A Clinical Monitoring and Outcomes Instrument for Chronic Pain Practice and Research. Journal of Pain Palliative Care Pharmacotherapy, 2004; 18(2):49-59.
    • Joish VN, Brixner DI. Back pain and productivity: measuring worker productivity from an employer's perspective. Journal of Pain and Palliative Care Pharmacotherapy, 2004; 18(2):79-85.
    • Joish VN, Malone DC, Wendel C, Mohler MJ. Profiling quality of diabetes care in a Veterans Affairs healthcare system. American Journal of Medical Quality, 2004; 19(3):112-120.
    • Kane S, Borisov NN, Brixner DI. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. The American Journal of Managed Care, 2004; 10(7):S216-226.
    • LaFleur J, Oderda G. Methods to measure Patient Compliance with Medication Regimens. Journal of Pain and Palliative Care Pharmacotherapy, 2004;18(3):81-7.
    • Oderda GM, Osterhaus JT. Outcomes and Economics in Pain Management, In Lipman A. (Ed.) Pain Management for Primary Care Clinicians, American Society Health Systems Pharmacists, 2004; 61:1490-3.
    • Young D, Bleyl K, Clark T, Oderda G, Liou T. Increasing pneumococcal vaccination rates among adult patients with cystic fibrosis. American Journal of Health Systems Pharmacists, 2004; 61:1490-3.
    • Epple C, Wright AL, Joish VN, Bauer M. The role of the active family nutritional support in Type II diabetes metabolic control. Diabetes Care, 2003; 26(10):2829-34.
    • Joish VN, Sahai A. Evaluating the role of confounding in pharmacoeconomic studies. Managed Care Interface, 2003; 16(12):L 30-35.
    • Joish VN, Malone DC, Miller JM. A cost benefit analysis of vision screening methods for preschoolers and school-aged children. Journal of American Association of Pediatric Ophthalmology & Strabismus, 2003; 7(4):283-290; (2004) Letter to the Editor & Reply, JAAPOS. 8:74-75.
    • Oderda GM. Cost-of-Illness Studies. Journal of Pain and Palliative Care Pharmacotherapy, 2003; 17(1):59-62.
    • Oderda G.M., Evans R.S., Lloyd J., Lipman A., Chen C., Ashburn M., Burke J., Samore M. Cost of Opioid Related Adverse Drug Events in Surgical Patients. Journal of Pain and Symptom Management, 2003; 25(3):276-83.
    • Brixner DI, Joish VN, Biskupiak JE, Shah H. (2008). Pharmacoeconomic Research in Managed Care in "Managed Care and Pharmacoeconomics" (Robert Navarro). 2nd edition, New York, Jones and Bartlett Publishers.
    • Brixner DI, Joish VN, Biskupiak JE, Shah H. (2006). "Pharmacoeconomic Research in Managed Care" in Managed Care Pharmacy Practice (Robert Navarro), New York, Aspen Publishers.
    • Brixner DI, Joish VN, Biskupiak JE, Shah H. (2008). Pharmacoeconomic Research in Managed Care in "Managed Care and Pharmacoeconomics" (Robert Navarro). 2nd edition, New York, Jones and Bartlett Publishers.
    • Brixner DI, Joish VN, Biskupiak JE, Shah H. (2006). "Pharmacoeconomic Research in Managed Care" in Managed Care Pharmacy Practice (Robert Navarro), New York, Aspen Publishers.